Literature DB >> 11602907

Differences in arterial and mixed venous IL-6 levels: the lungs as a source of cytokine storm in sepsis.

J G Tyburski1, C Dente, R F Wilson, C Steffes, J Devlin, A M Carlin, L M Flynn, C Shanti.   

Abstract

BACKGROUND: Several investigators have shown that blood levels of interleukin 6 (IL-6) correlate with the severity of illness in critically ill or injured patients. However, little is known about differential arterial and venous blood levels of the cytokine, especially across the lungs.
METHODS: We measured differences in IL-6 levels in pulmonary and systemic arterial blood and then documented the production or elimination of IL-6 by the lungs in 19 patients with severe illness. Prospective data were obtained from multiple, simultaneous systemic arterial (ART) and mixed venous (MV) blood samples that were drawn for IL-6 analysis from systemic arterial and pulmonary artery catheters in 7 patients awaiting vascular operation and in 12 trauma patients being treated in the intensive care unit.
RESULTS: A lung disorder was present in 5 patients (pneumonia [n = 1], lung trauma [n = 4]) and absent in the remaining 14 patients. The following data were obtained (mean +/- SD) from the highest MV IL-6 levels (pg/mL) in each patient. In patients with a lung disorder (n = 5) compared with those with no disorder (n = 14), ART IL-6 was 9309 +/- 12,521 versus 134 +/- 128 (P =.010), MV IL-6 was 5516 +/- 7420 versus 137 +/- 129 (P =.011), the absolute difference was 3793 +/- 5271 versus -3 +/- 15 (P =.011), and the percentage difference was 37.4% +/- 29.8% versus 1.5% +/- 12.3% (P =.001). The ART and MV IL-6 levels tended to be much higher in the 5 patients with pneumonia (n = 1) and lung injuries (n = 4) than in the patients without apparent pulmonary problems. In addition, the patients with a primary lung disorder demonstrated a net increase in IL-6 levels across the lungs, whereas there was no increase, but rather, a net reduction of IL-6 levels across the lungs in patients without a lung disorder.
CONCLUSIONS: The lung appears to be a major producer of IL-6 in patients with an inflammatory lung process. There is a 39% increase in the level of IL-6 as it passes through inflamed lung, producing a marked difference in ART and MV IL-6 levels. Normal lung demonstrated little effect on either ART or MV IL-6 levels.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11602907     DOI: 10.1067/msy.2001.118094

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  5 in total

1.  Functionalized single-walled carbon nanotubes cause reversible acute lung injury and induce fibrosis in mice.

Authors:  Yanli Zhang; Jiejie Deng; Yanxu Zhang; Feng Guo; Chenggang Li; Zhen Zou; Wen Xi; Jun Tang; Yang Sun; Peng Yang; Zongsheng Han; Dangsheng Li; Chengyu Jiang
Journal:  J Mol Med (Berl)       Date:  2012-08-10       Impact factor: 4.599

2.  Effect of continuous hemofiltration on hemodynamics, lung inflammation and pulmonary edema in a canine model of acute lung injury.

Authors:  Xiao Su; Chunxue Bai; Qunying Hong; Duming Zhu; Lixian He; Jianping Wu; Feng Ding; Xiaohui Fang; Michael A Matthay
Journal:  Intensive Care Med       Date:  2003-10-14       Impact factor: 17.440

3.  Beneficial and detrimental effects of plasmin(ogen) during infection and sepsis in mice.

Authors:  Yongzhi Guo; Jinan Li; Elin Hagström; Tor Ny
Journal:  PLoS One       Date:  2011-09-12       Impact factor: 3.240

4.  Differences of plasma IL-1 and TNF-α in healthy Chinese Population.

Authors:  Jintao Yuan; Lan Wang; Yijin Lin; Jianhong Chen; Jianghong Hu
Journal:  Open Med (Wars)       Date:  2015-06-09

5.  Corticosteroid treatment ameliorates acute lung injury induced by 2009 swine origin influenza A (H1N1) virus in mice.

Authors:  Chenggang Li; Penghui Yang; Yanli Zhang; Yang Sun; Wei Wang; Zhen Zou; Li Xing; Zhongwei Chen; Chong Tang; Feng Guo; Jiejie Deng; Yan Zhao; Yiwu Yan; Jun Tang; Xiliang Wang; Chengyu Jiang
Journal:  PLoS One       Date:  2012-08-29       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.